Main menu button

News

Equity Research Candles Scandinavia Q1 2023/24: Cautious customers
30 Aug 2023
Equity Research Candles Scandinavia Q1 2023/24: Cautious customers
Equity Research Candles Scandinavia
Equity Research Svenska Aerogel, Q2 2023: Lower than expected revenues but positive development with key customers
30 Aug 2023
Equity Research Svenska Aerogel, Q2 2023: Lower than expected revenues but positive development with key customers
Equity Research Svenska Aerogel
Carlsquare weekly market letter: September is Christmas for traders
30 Aug 2023
Carlsquare weekly market letter: September is Christmas for traders
Equity Research Carlsquare
Candles Scandinavia: CEO interviewed on the Q1 2023/2024-report
28 Aug 2023
Candles Scandinavia: CEO interviewed on the Q1 2023/2024-report
Equity Research Candles Scandinavia
Initiation of coverage Nosa Plugs: Smelling success, plugging a hole in the market
28 Aug 2023
Initiation of coverage Nosa Plugs: Smelling success, plugging a hole in the market
Equity Research Nosa Plugs
Carlsquare hat Frank Otto bei einem Millioneninvestment in die Synbiotic SE begleitet und gleichzeitig ihn und die anderen Gesellschafter der CannaCare Health GmbH bei der Fusion mit der SynBiotic SE beraten
25 Aug 2023
Carlsquare hat Frank Otto bei einem Millioneninvestment in die Synbiotic SE begleitet und gleichzeitig ihn und die anderen Gesellschafter der CannaCare Health GmbH bei der Fusion mit der SynBiotic SE beraten
Deal News
Equity Research Zazz Energy, Q2 2023: Intense quarter and restart expected soon
25 Aug 2023
Equity Research Zazz Energy, Q2 2023: Intense quarter and restart expected soon
Equity Research
Equity research Observit, Q2 2023: Strong performance from software company
24 Aug 2023
Equity research Observit, Q2 2023: Strong performance from software company
Equity Research Observit
Equity Research Zazz Energy, Q2 2023: Intensive quarter awaiting the restart of the Amfilochia plant
23 Aug 2023
Equity Research Zazz Energy, Q2 2023: Intensive quarter awaiting the restart of the Amfilochia plant
Equity Research
Equity Research, Pharmiva: Merger with Peptonic could spark the fire
23 Aug 2023
Equity Research, Pharmiva: Merger with Peptonic could spark the fire
Equity Research
Carlsquare weekly market letter: China and the US are dithering. The boat is rocking
23 Aug 2023
Carlsquare weekly market letter: China and the US are dithering. The boat is rocking
Equity Research Carlsquare
Equity research Observit, Q2 2023: Strong performance from software company
22 Aug 2023
Equity research Observit, Q2 2023: Strong performance from software company
Equity Research Observit
Equity research update Kancera: Heart infarction results expected soon
22 Aug 2023
Equity research update Kancera: Heart infarction results expected soon
Equity Research Kancera
Research Update InCoax, Q2 2023: A potential new Tier 1 operating customer
21 Aug 2023
Research Update InCoax, Q2 2023: A potential new Tier 1 operating customer
Equity Research InCoax
Research Update Ecoclime, Q2 2023: Sales growth much better than expected
18 Aug 2023
Research Update Ecoclime, Q2 2023: Sales growth much better than expected
Equity Research
First Impression InCoax, Q2 2023: Sales lower than expected, but good gross margin
18 Aug 2023
First Impression InCoax, Q2 2023: Sales lower than expected, but good gross margin
Equity Research InCoax
Equity research Risk Intelligence, Q2 2023: A strong quarter throughout
18 Aug 2023
Equity research Risk Intelligence, Q2 2023: A strong quarter throughout
Equity Research Risk Intelligence
First Impression Ecoclime, Q2 2023: 34% higher revenues than expected
17 Aug 2023
First Impression Ecoclime, Q2 2023: 34% higher revenues than expected
Equity Research
Research Update Biosergen, Q2 2023: Stable in costs but delays in clinical timeline
16 Aug 2023
Research Update Biosergen, Q2 2023: Stable in costs but delays in clinical timeline
Equity Research Biosergen
Equity Research Risk Intelligence, Q2 2023: Better than expected revenues and profitability
16 Aug 2023
Equity Research Risk Intelligence, Q2 2023: Better than expected revenues and profitability
Equity Research Risk Intelligence